CyberKnife SBRT for Prostate Cancer
(CK-DESPOT Trial)
Trial Summary
What is the purpose of this trial?
Stereotactic body radiation therapy (SBRT) has been employed in the treatment of prostate cancer. Multiple single institution experiences suggest high biochemical control rates with acceptable toxicity in low risk prostate cancer but efficacy data in unfavorable type prostate cancer is less convincing. CyberKnife-SBRT (CK-SBRT) can be used to escalate radiation dose delivery to the prostate while sparing normal tissue.
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, it does mention that you should not have any medical or psychiatric illnesses that would interfere with treatment or follow-up, which might imply some medication adjustments. Please consult with the trial coordinators for specific guidance.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the idea that CyberKnife SBRT for Prostate Cancer is an effective treatment?
The available research shows that CyberKnife SBRT is an effective treatment for prostate cancer. Studies have reported promising outcomes with minimal side effects. For example, one study highlights that CyberKnife SBRT can deliver a large dose of radiation in fewer sessions, which is beneficial for patients with low- and intermediate-risk prostate cancer. Another study compares CyberKnife to another method called Tomotherapy and suggests that CyberKnife provides favorable results. Overall, the research indicates that CyberKnife SBRT is a promising option for treating prostate cancer.12345
What data supports the effectiveness of the treatment CyberKnife SBRT for prostate cancer?
What safety data is available for CyberKnife SBRT in prostate cancer treatment?
Several studies have evaluated the safety of CyberKnife SBRT for prostate cancer. A retrospective study focused on the safety and feasibility of this treatment. A ten-year analysis of SBRT for low-risk prostate cancer reported on efficacy and toxicity, involving 230 patients treated with CyberKnife SBRT. Another study on low and intermediate-risk prostate cancer found that while some patients experienced acute genitourinary toxicity and proctitis, the treatment was generally safe and effective. A five-year follow-up study on older patients or those with comorbidities reported favorable survival and toxicity outcomes, with no grade 3 or higher acute complications and minimal late urinary toxicity. Overall, these studies suggest that CyberKnife SBRT is a safe treatment option for prostate cancer.56789
Is CyberKnife SBRT safe for treating prostate cancer?
Is CyberKnife SBRT a promising treatment for prostate cancer?
Yes, CyberKnife SBRT is a promising treatment for prostate cancer. It uses advanced technology to target cancer cells precisely, minimizing damage to healthy tissue. This treatment is effective for low- to intermediate-risk prostate cancer and can deliver high doses in fewer sessions, making it convenient for patients.1251011
How is CyberKnife SBRT treatment different from other prostate cancer treatments?
CyberKnife SBRT is unique because it uses a robotic system to deliver precise, high doses of radiation in fewer sessions, minimizing damage to surrounding healthy tissue. This approach, known as hypofractionation, is particularly effective for prostate cancer due to its specific biological characteristics.1251011
Research Team
Rachelle Lanciano, MD
Principal Investigator
Philadelphia CyberKnife -Crozer Health
Rachelle Lanciano, MD
Principal Investigator
Philadelphia CyberKnife -Crozer Health
Eligibility Criteria
Men with a specific type of prostate cancer that hasn't spread, diagnosed within the last year. They should have a prostate size less than 100 cc, low urinary symptoms (AUA score <20), and no prior major prostate surgeries or pelvic radiation. Men who've had other cancers besides non-melanoma skin cancer in the past 5 years or those with implanted hardware near the prostate are not eligible.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive CyberKnife-SBRT with an escalated dose of 40 Gy in 5 fractions over 7-10 days
Follow-up
Participants are monitored for safety and effectiveness after treatment, including overall survival and toxicity
Treatment Details
Interventions
- CyberKnife SBRT
CyberKnife SBRT is already approved in United States, European Union, Canada, United Kingdom for the following indications:
- Low-risk prostate cancer
- Intermediate-risk prostate cancer
- Localized prostate cancer
- Early-stage prostate cancer
- Prostate cancer
- Localized prostate cancer
- Intermediate-risk prostate cancer
- High-risk prostate cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Crozer-Keystone Health System
Lead Sponsor